BriaCell Therapeutics (BCT) Q1 2025 earnings summary

Executive summary

• Advanced pivotal Phase 3 trial for Bria-IMT™ in metastatic breast cancer, with 35 clinical sites active and enrolling patients; interim data pending after 144 events.

• Reported 55% one-year survival rate in Phase 2 for Bria-IMT™, exceeding standard of care benchmarks.

• Initiated Phase 1/2 study for Bria-OTS™, a next-generation personalized immunotherapy.

• Closed public offerings in September, October, and December 2024, raising over $19 million gross to support operations.

• Net loss of $5.8 million for Q1 2025, compared to net income of $6.0 million in Q1 2024, primarily due to changes in warrant liability valuation.

Financial highlights

• Total assets increased to $10.4 million as of October 31, 2024, from $5.9 million at July 31, 2024.

• Cash and cash equivalents rose to $5.8 million, up from $0.9 million at prior year-end.

• Operating expenses decreased to $5.2 million from $8.5 million year-over-year, driven by lower R&D and G&A costs.

• Research and development expenses fell to $3.7 million from $6.9 million, reflecting the conclusion of earlier trials and focus on Phase 3.

• General and administrative expenses decreased to $1.5 million from $1.6 million year-over-year.

• Net loss per share was $(0.22) basic and diluted, compared to $0.38 basic and $(0.50) diluted in the prior year.

Outlook and guidance

• Focus remains on advancing the pivotal Phase 3 Bria-IMT™ trial and progressing Bria-OTS™ clinical development.

• Management continues to seek additional capital to fund operations and clinical programs.

• Ongoing cost management and resource allocation to prioritize clinical milestones.